Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease
- BREAKOUT Study is Palatin's third clinical program for the potential treatment of inflammatory diseases with melanocortin agonists - Primary en...
- BREAKOUT Study is Palatin's third clinical program for the potential treatment of inflammatory diseases with melanocortin agonists - Primary endpoint of the BREAKOUT Study is a 50% reduction in urine protein/creatinine (UP/Cr) ratio after six months of combined therapy (RAAS inhibition therapy plus bremelanotide) CRANBURY, N.J., Jan. 19, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the initiation of a Phase 2b clinical trial with the melanocortin agonist, bremelanotide.